Takeda

Takeda’s Lexington operations are part of the global biopharmaceutical company’s Massachusetts footprint and are listed under research, product development and manufacturing. The company describes itself as patient-focused and R&D-driven, with a mission of bringing Better Health and a Brighter Future. Its medicines span areas including rare diseases, cancers, gastrointestinal conditions, neuroscience and plasma-derived therapies, and recent company news highlights late-stage oncology data presented at the ESMO 2026 congress.

Founded in Osaka, Japan, in 1781, Takeda has grown into one of the world’s largest pharmaceutical companies, and its 2019 acquisition of Shire, which had a significant presence in Lexington, expanded its operations in the town. The company emphasizes quality and safety in its plasma-derived medicines. Recent milestones include U.S. approvals for first-in-class treatments for polycythemia vera and narcolepsy type 1, along with a priority FDA review of zasocitinib, an oral once-daily pill for plaque psoriasis.

What to Know

• Takeda is headquartered in Japan, with its U.S. hub in Cambridge.
• The company runs global corporate social responsibility programs focused on climate-ready health care.
• Investors can follow results through Takeda’s investor newsletter.
• The Lexington operations are listed with the Lexington Chamber of Commerce.